%0 Journal Article %A YOSHIYUKI KENMOTSU %A FUMIHIRO OSHITA %A MAKIKO SUGIURA %A SHUJI MURAKAMI %A TETSURO KONDO %A HARUHIRO SAITO %A KOUZO YAMADA %T Nedaplatin and Irinotecan in Patients with Large-cell Neuroendocrine Carcinoma of the Lung %D 2012 %J Anticancer Research %P 1453-1456 %V 32 %N 4 %X Background: No standard chemotherapy has been established for patients with large-cell neuroendocrine carcinoma (LCNEC). Patients and Methods: Patients with LCNEC of the lung were treated with nedaplatin (NP) at 50 mg/m2 and irinotecan at 50 mg/m2 on days 1 and 8 every four weeks for four cycles. Results: Data for 18 of the LCNEC patients were retrospectively analyzed. All patients were male, with a performance status 0 or 1, and the median age was 68 (range 58-80) years. Nine patients received adjuvant chemotherapy after undergoing complete surgical resection. Fourteen patients were able to receive four cycles of nedaplatin and irinotecan. Grade 4 leukopenia and neutropenia occurred in 5.6% and 16.7%, respectively. Four patients experienced grade 3 non-hematologic toxicities, such as diarrhea, enterocolitis, duodenal perforation and myocardial infarction. There were no treatment-related deaths. Two patients achieved complete response and four achieved partial response, and the median survival time was 12.3 months for the nine patients with advanced disease. Conclusion: Nedaplatin plus irinotecan is effective and safe for patients with LCNEC of the lung. %U https://ar.iiarjournals.org/content/anticanres/32/4/1453.full.pdf